UNLABELLED: KLF6-SV1 (SV1), the major splice variant of KLF6, antagonizes the KLF6 tumor suppressor by an unknown mechanism. Decreased KLF6 expression in human hepatocellular carcinoma (HCC) correlates with increased mortality, but the contribution of increased SV1 is unknown. We sought to define the impact of SV1 on human outcomes and experimental murine hepatocarcinogenesis and to elucidate its mechanism of action. In hepatitis C virus (HCV)-related HCC, an increased ratio of SV1/KLF6 within the tumor was associated with features of more advanced disease. Six months after a single injection of diethylnitrosamine (DEN), SV1 hepatocyte transgenic mice developed more histologically advanced tumors, whereas Klf6-depleted mice developed bigger tumors compared to the Klf6fl(+/+) control mice. Nine months after DEN, SV1 transgenic mice with Klf6 depletion had the greatest tumor burden. Primary mouse hepatocytes from both the SV1 transgenic animals and those with hepatocyte-specific Klf6 depletion displayed increased DNA synthesis, with an additive effect in hepatocytes harboring both SV1 overexpression and Klf6 depletion. Parallel results were obtained by viral SV1 transduction and depletion of Klf6 through adenovirus-Cre infection of primary Klf6fl(+/+) hepatocytes. Increased DNA synthesis was due to both enhanced cell proliferation and increased ploidy. Coimmunoprecipitation studies in 293T cells uncovered a direct interaction of transfected SV1 with KLF6. Accelerated KLF6 degradation in the presence of SV1 was abrogated by the proteasome inhibitor MG132. CONCLUSION: An increased SV1/KLF6 ratio correlates with more aggressive HCC. In mice, an increased SV1/KLF6 ratio, generated either by increasing SV1, decreasing KLF6, or both, accelerates hepatic carcinogenesis. Moreover, SV1 binds directly to KLF6 and accelerates its degradation. These findings represent a novel mechanism underlying the antagonism of tumor suppressor gene function by a splice variant of the same gene.
UNLABELLED: KLF6-SV1 (SV1), the major splice variant of KLF6, antagonizes the KLF6tumor suppressor by an unknown mechanism. Decreased KLF6 expression in humanhepatocellular carcinoma (HCC) correlates with increased mortality, but the contribution of increased SV1 is unknown. We sought to define the impact of SV1 on human outcomes and experimental murinehepatocarcinogenesis and to elucidate its mechanism of action. In hepatitis C virus (HCV)-related HCC, an increased ratio of SV1/KLF6 within the tumor was associated with features of more advanced disease. Six months after a single injection of diethylnitrosamine (DEN), SV1 hepatocyte transgenic mice developed more histologically advanced tumors, whereas Klf6-depleted mice developed bigger tumors compared to the Klf6fl(+/+) control mice. Nine months after DEN, SV1 transgenic mice with Klf6 depletion had the greatest tumor burden. Primary mouse hepatocytes from both the SV1 transgenic animals and those with hepatocyte-specific Klf6 depletion displayed increased DNA synthesis, with an additive effect in hepatocytes harboring both SV1 overexpression and Klf6 depletion. Parallel results were obtained by viral SV1 transduction and depletion of Klf6 through adenovirus-Cre infection of primary Klf6fl(+/+) hepatocytes. Increased DNA synthesis was due to both enhanced cell proliferation and increased ploidy. Coimmunoprecipitation studies in 293T cells uncovered a direct interaction of transfected SV1 with KLF6. Accelerated KLF6 degradation in the presence of SV1 was abrogated by the proteasome inhibitor MG132. CONCLUSION: An increased SV1/KLF6 ratio correlates with more aggressive HCC. In mice, an increased SV1/KLF6 ratio, generated either by increasing SV1, decreasing KLF6, or both, accelerates hepatic carcinogenesis. Moreover, SV1 binds directly to KLF6 and accelerates its degradation. These findings represent a novel mechanism underlying the antagonism of tumor suppressor gene function by a splice variant of the same gene.
Authors: Daniela A Slavin; Nicolás P Koritschoner; Claudio C Prieto; Fernando J López-Díaz; Bruno Chatton; José Luis Bocco Journal: Oncogene Date: 2004-10-28 Impact factor: 9.867
Authors: G Narla; K E Heath; H L Reeves; D Li; L E Giono; A C Kimmelman; M J Glucksman; J Narla; F J Eng; A M Chan; A C Ferrari; J A Martignetti; S L Friedman Journal: Science Date: 2001-12-21 Impact factor: 47.728
Authors: Analisa DiFeo; Goutham Narla; Jennifer Hirshfeld; Olga Camacho-Vanegas; Jyothsna Narla; Stephen L Rose; Tamara Kalir; Shen Yao; Alice Levine; Michael J Birrer; Tomas Bonome; Scott L Friedman; Richard E Buller; John A Martignetti Journal: Clin Cancer Res Date: 2006-06-15 Impact factor: 12.531
Authors: Goutham Narla; Analisa Difeo; Helen L Reeves; Daniel J Schaid; Jennifer Hirshfeld; Eldad Hod; Amanda Katz; William B Isaacs; Scott Hebbring; Akira Komiya; Shannon K McDonnell; Kathleen E Wiley; Steven J Jacobsen; Sarah D Isaacs; Patrick C Walsh; S Lilly Zheng; Bao-Li Chang; Danielle M Friedrichsen; Janet L Stanford; Elaine A Ostrander; Arul M Chinnaiyan; Mark A Rubin; Jianfeng Xu; Stephen N Thibodeau; Scott L Friedman; John A Martignetti Journal: Cancer Res Date: 2005-02-15 Impact factor: 12.701
Authors: Yong Gu Cho; Chang Jae Kim; Cho Hyun Park; Young Mok Yang; Su Young Kim; Suk Woo Nam; Sug Hyung Lee; Nam Jin Yoo; Jung Young Lee; Won Sang Park Journal: Oncogene Date: 2005-06-30 Impact factor: 9.867
Authors: Lars P Bechmann; Amalia Gastaldelli; Diana Vetter; Gillian L Patman; Laura Pascoe; Rebekka A Hannivoort; Ursula E Lee; Isabel Fiel; Ursula Muñoz; Demetrio Ciociaro; Young-Min Lee; Emma Buzzigoli; Luca Miele; Kei Y Hui; Elisabetta Bugianesi; Alastair D Burt; Christopher P Day; Andrea Mari; Loranne Agius; Mark Walker; Scott L Friedman; Helen L Reeves Journal: Hepatology Date: 2012-03-01 Impact factor: 17.425
Authors: Sigal Kremer-Tal; Helen L Reeves; Goutham Narla; Swan N Thung; Myron Schwartz; Analisa Difeo; Amanda Katz; Jordi Bruix; Paulette Bioulac-Sage; John A Martignetti; Scott L Friedman Journal: Hepatology Date: 2004-11 Impact factor: 17.425
Authors: Gennadi V Glinsky; Anna B Glinskii; Andrew J Stephenson; Robert M Hoffman; William L Gerald Journal: J Clin Invest Date: 2004-03 Impact factor: 14.808
Authors: Carmen Berasain; María Elizalde; Raquel Urtasun; Josefa Castillo; Oihane García-Irigoyen; Iker Uriarte; Maria U Latasa; Jesús Prieto; Matías A Avila Journal: Hepat Oncol Date: 2014-03-20
Authors: Lars P Bechmann; Diana Vetter; Junichi Ishida; Rebekka A Hannivoort; Ursula E Lang; Peri Kocabayoglu; M Isabel Fiel; Ursula Muñoz; Gillian L Patman; Fengxia Ge; Shoshana Yakar; Xiaosong Li; Loranne Agius; Young-Min Lee; Weijia Zhang; Kei Yiu Hui; Despina Televantou; Gary J Schwartz; Derek LeRoith; Paul D Berk; Ryozo Nagai; Toru Suzuki; Helen L Reeves; Scott L Friedman Journal: J Hepatol Date: 2013-01-23 Impact factor: 25.083
Authors: Raheleh Hatami; Anieta M Sieuwerts; Sudeh Izadmehr; Zhong Yao; Rui Fang Qiao; Luena Papa; Maxime P Look; Marcel Smid; Jessica Ohlssen; Alice C Levine; Doris Germain; David Burstein; Alexander Kirschenbaum; Analisa DiFeo; John A Foekens; Goutham Narla Journal: Sci Transl Med Date: 2013-01-23 Impact factor: 17.956